Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000810243 | SCV000950436 | uncertain significance | Hermansky-Pudlak syndrome 9 | 2021-08-27 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine with glutamic acid at codon 131 of the BLOC1S6 protein (p.Lys131Glu). The lysine residue is highly conserved and there is a small physicochemical difference between lysine and glutamic acid. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with BLOC1S6-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004962831 | SCV005538110 | uncertain significance | Inborn genetic diseases | 2024-08-19 | criteria provided, single submitter | clinical testing | The c.391A>G (p.K131E) alteration is located in exon 4 (coding exon 4) of the BLOC1S6 gene. This alteration results from a A to G substitution at nucleotide position 391, causing the lysine (K) at amino acid position 131 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |